scholarly journals Diurnal panic attacks with and without nocturnal panic attacks: are there some phenomenological differences?

2005 ◽  
Vol 27 (3) ◽  
pp. 216-221 ◽  
Author(s):  
Fabiana L Lopes ◽  
Antonio E Nardi ◽  
Isabella Nascimento ◽  
Alexandre M Valença ◽  
Marco A Mezzasalma ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Attention Deficit Disorder ◽  
Panic Attack ◽  
Age At Onset ◽  
Term Treatment ◽  
Panic Attacks ◽  
Short Term ◽  
Short Term Treatment ◽  
Term Outcome ◽  
Cross Sectional

OBJECTIVE: To compare nocturnal and diurnal panic attacks in a cross-sectional study and in a longitudinal prospective short-term follow-up. METHODS: We selected 57 panic disorder (PD) subjects (DSM-IV) and rated them with the Panic Disorder Severity Scale (PDSS) at baseline and after 30 days of treatment with nortriptyline, and with the Eysenck Personality Inventory and the Brown Attention Deficit Disorder (ADD) Scale at baseline. RESULTS: The sample was divided into a nocturnal and diurnal panic attack (NDPA) group - 57.9% (n = 33) - and a diurnal panic attack (DPA) group - 42.1% (n = 24). The groups showed a similar mean age at onset of PD and a pattern of prominent respiratory symptoms. The PDSS did not differ between the groups following short-term treatment (p = 0.451). There were also neither significant differences in Neuroticism (p = 0.094) and Extroversion (p = 0.269) nor in the Brown ADD Scale (p = 0.527). CONCLUSION: In our study, patients with both nocturnal and diurnal panic attacks showed similar features in their phenomenology and short-term outcome when compared to pure diurnal panic attacks patients.

Baseline Heartbeat Perception Accuracy and Short-Term Outcome of Brief Cognitive-Behaviour Therapy for Panic Disorder with Agoraphobia

2013 ◽  
Vol 43 (4) ◽  
pp. 426-435 ◽  
Author(s):  
Vasilios G. Masdrakis ◽  
Emilia-Maria Legaki ◽  
Nikolaos Vaidakis ◽  
Dimitrios Ploumpidis ◽  
Constantin R. Soldatos ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Cognitive Behaviour Therapy ◽  
Acute Treatment ◽  
Panic Attacks ◽  
Behaviour Therapy ◽  
Short Term ◽  
Term Outcome ◽  
Heartbeat Perception ◽  
Short Term Outcome ◽  
Cognitive Behaviour

Background: Increased heartbeat perception accuracy (HBP-accuracy) may contribute to the pathogenesis of Panic Disorder (PD) without or with Agoraphobia (PDA). Extant research suggests that HBP-accuracy is a rather stable individual characteristic, moreover predictive of worse long-term outcome in PD/PDA patients. However, it remains still unexplored whether HBP-accuracy adversely affects patients’ short-term outcome after structured cognitive behaviour therapy (CBT) for PD/PDA. Aim: To explore the potential association between HBP-accuracy and the short-term outcome of a structured brief-CBT for the acute treatment of PDA. Method: We assessed baseline HBP-accuracy using the “mental tracking” paradigm in 25 consecutive medication-free, CBT-naive PDA patients. Patients then underwent a structured, protocol-based, 8-session CBT by the same therapist. Outcome measures included the number of panic attacks during the past week, the Agoraphobic Cognitions Questionnaire (ACQ), and the Mobility Inventory-Alone subscale (MI-alone). Results: No association emerged between baseline HBP-accuracy and posttreatment changes concerning number of panic attacks. Moreover, higher baseline HBP-accuracy was associated with significantly larger reductions in the scores of the ACQ and the MI-alone scales. Conclusion: Our results suggest that in PDA patients undergoing structured brief-CBT for the acute treatment of their symptoms, higher baseline HBP-accuracy is not associated with worse short-term outcome concerning panic attacks. Furthermore, higher baseline HBP-accuracy may be associated with enhanced therapeutic gains in agoraphobic cognitions and behaviours.

A 15-year follow-up study of patients with panic disorder

2003 ◽  
Vol 18 (8) ◽  
pp. 401-408 ◽  
Author(s):  
Sven Andersch ◽  
Jerker Hetta
Keyword(s):  
Panic Disorder ◽  
Favourable Outcome ◽  
Drug Trial ◽  
Panic Attacks ◽  
Daily Functioning ◽  
Short Term Treatment ◽  
Term Outcome ◽  
Long Term Outcome

AbstractBackgroundPanic disorder (PD) is generally regarded as a chronic condition with considerable variation in severity of symptoms.AimsTo describe the long-term outcome of naturalistically treated PD.MethodsFifty-five outpatients with PD, who participated in a placebo-controlled drug trial of the efficacy of alprazolam and imipramine 15 years ago were reassessed with the same instruments used in the original study.ResultsComplete recovery (no panic attacks and no longer on medication during the last 10 years) was seen in 18% of patients, and an additional 13% recovered but were still on medication. Fifty-one percent experienced recurrent anxiety attacks whereas 18% still met diagnostic criteria for PD. The incidence of agoraphobia decreased from 69% to 20%. Patients with agoraphobia at admission tended to have a poorer long-term outcome according to daily functioning compared with patients without agoraphobia at admission, although both groups reported improved daily functioning at follow-up. Maintenance medication was common. No benzodiazepine abuse was reported.ConclusionPD has a favourable outcome in a substantial proportion of patients. However, the illness is chronic and needs treatment. The short-term treatment given in the drug trial had no influence on the long-term outcome.

Predictors of short-term treatment response in 66 patients with panic disorder

1994 ◽  
Vol 30 (4) ◽  
pp. 233-241 ◽  
Author(s):  
Donald W. Black ◽  
Robert B. Wesner ◽  
Janelle Gabel ◽  
Wayne Bowers ◽  
Patrick Monahan
Keyword(s):  
Panic Disorder ◽  
Treatment Response ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

scholarly journals Carbon dioxide induced panic attacks and short term clonazepam treatment: preliminary study

1999 ◽  
Vol 57 (2B) ◽  
pp. 361-365 ◽  
Author(s):  
ANTONIO EGIDIO NARDI ◽  
ALEXANDRE M. VALENÇA ◽  
WALTER ZIN ◽  
ISABELLA NASCIMENTO
Keyword(s):  
Carbon Dioxide ◽  
Panic Disorder ◽  
Panic Attack ◽  
Challenge Test ◽  
Panic Attacks ◽  
Short Term ◽  
Compressed Gas ◽  
Gas Inhalation ◽  
Drug Free ◽  
Clonazepam Therapy

AIMS: 1. To verify the sensibility of panic patients to a mixture of 35% CO2 and 65% O2. 2. To determine if a ten days treatment with clonazepam attenuates the panic attacks induced by the inhalation of 35% carbon dioxide in panic disorder. METHOD: We randomly selected six panic disorder subjects, using the Structured Clinical Interview for DSM-IV. All subjects went double-blindly through an inhalation of 35% CO2 and compressed gas (atmospheric air) on two occasions. First, at baseline, when they were drug free. Second, after a 10 days clonazepam treatment. RESULTS: Neither at baseline nor after treatment any patient had a panic attack during compressed gas inhalation. At the first test five patients (83.3%) had a severe panic attack with high levels of subjective anxiety during carbon dioxide inhalation. After 9.6 (± 3.4) days of clonazepam treatment, only two (33.3%) patients experienced a mild panic attack. CONCLUSION: This pilot study suggests the efficacy of the short term clonazepam therapy in attenuating panic attacks and supports the usefulness of the 35% carbon dioxide challenge test as an analogue method for study the efficacy of anti-panic drugs. Further placebo-controlled studies to pharmacological treatment are warranted.

scholarly journals Venlafaxine extended-release capsules in panic disorder

2005 ◽  
Vol 187 (4) ◽  
pp. 352-359 ◽  
Author(s):  
Jacques Bradwejn ◽  
Antti Ahokas ◽  
Dan J. Stein ◽  
Eliseo Salinas ◽  
Gerard Emilien ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Panic Disorder ◽  
Extended Release ◽  
Term Treatment ◽  
Panic Attacks ◽  
Double Blind Study ◽  
Short Term Treatment ◽  
Double Blind ◽  
Proven Efficacy ◽  
To Receive

BackgroundVenlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder.AimsTo evaluate the efficacy, safety and tolerability of venlafaxine ER in treating panic disorder.MethodAdult out-patients (n=361) with panic disorder were randomly assigned to receive venlafaxine ER (75–225 mg/day) or placebo for up to 10 weeks in a double-blind study.ResultsVenlafaxine ER was not associated with a greater proportion of patients free from full-symptom panic attacks at the finalon-therapy evaluation, but was associated with lower mean panic attack frequency and a higher proportion free from limited-symptom panic attacks, higher response and remission rates, and improvements in anticipatory anxiety, fear and avoidance. Adverse events were comparable with those of the drug in depression and anxiety disorders.ConclusionsVenlafaxine ER seems to be effective and well tolerated in the short-term treatment of panic disorder.

Sign in / Sign up

Export Citation Format

Share Document